Yüksek Doz Trimetazidin ile İntihar Girişimi: Olgu Sunumu

Hakan Demirci; Yaşar Küçükardalı; Hakan Terekeci; Emrullah Solmazgül

Suicide Attempt With High-Dose Trimetazidine: Case Report

Year 2008, Volume: 2008 Issue: 3, 249 - 251, 01.03.2008

Hakan Demirci Yaşar Küçükardalı Hakan Terekeci Emrullah Solmazgül

Abstract

A 20-year-old otherwise healthy male patient with depression had ingested 1200 mg (60 tablets) of trimetazidine. He was taken to the emergency unit of our institution by his relatives four hours after the ingestion and gastric decontamination was done by gastric lavage and application of 50 g activated charcoal. Follow-up was unremarkable except sleepiness and a brief period of hypotension. No life-threatening risk was observed following oral ingestion of high-dose trimetazidine when the patient was treated after four hours. Turkish Başlık: Yüksek Doz Trimetazidin ile İntihar Girişimi: Olgu Sunumu Anahtar Kelimeler: Trimetazidin (TMZ); intoksikasyon; intihar; depresyon Daha önce depresyon dışında bilinen bir hastalığı olmayan 20 yaşında erkek hasta, intihar amaçlı 1200 mg (60 tablet) trimetazidini oral olarak almış. Alımdan dört saat sonra hastanemiz acil servisine yakınları tarafından getirilen hastaya gastrik dekontaminasyon (gastrik lavaj ve 50 gr aktif kömür) uygulandı. Hastanın izleminde uykululuk hali ve kısa süreli hipotansiyon dışında bulgu saptanmadı. Yüksek dozda trimetazidinin oral alımından dört saat sonra müdahale edildiğinde yaşamı tehdit eden risk oluşturmadığı gözlenmiştir.

Keywords

Trimetazidine (TMZ); intoxication; suicide; depression.

References

1. McCormack JG, Stanley WC, Wolff AA. Ranolazine: a novel metabolic modulator for the treatment of angina. Gen Pharmacol 1998;30:639-45.
2. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, et al. Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 2000;47:688-96.
3. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8.
4. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group. Br J Clin Pharmacol 1994; 37:279-88.
5. Mody FV, Singh BN, Mohiuddin IH, Coyle KB, Buxton DB, Hansen HW, et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998;82:42K-49K.
6. Lopaschuk GD. Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coron Artery Dis 2001;12 Suppl 1:8-11.
7. Martí Massó JF, Martí I, Carrera N, Poza JJ, López de Munain A. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 2005;60:419-22.
8. Sommet A, Azaïs-Vuillemin C, Bagheri H, Rascol O, Montastruc JL. Trimetazidine: a new cause for druginduced parkinsonism? Mov Disord 2005;20:1080-1.
9. Martí Massó JF. Trimetazidine-induced parkinsonism. Neurologia 2004;19:392-5. [Abstract]
10. Masmoudi K, Gras-Champel V, Douadi Y, Masson H, Andréjak M. Trimetazidine-a new aetiology for extrapyramidal disorders: A case of parkinsonism and akathisia. Therapie 2005;60:603-5. [Abstract]
11. Sustained release trimetazidine pharmaceutical compositions and a method of their preparation. Available from: http://www.freepatentsonline.com/ EP1195160.html [Erişim tarihi: 19.11.2008].